13 results on '"Feaster, Daniel J."'
Search Results
2. Psychosocial Factors Linked to Uncontrolled Infection and Mortality among People Living with HIV Who Use Substances: A Latent Class Analysis
- Author
-
Schmidt, Renae D., Horigian, Viviana E., Duan, Rui, Traynor, Sharleen T., Davis, Carly A., Gonzalez, Sophia T., Forney, Derrick J., Mandler, Raul, Del Rio, Carlos, Metsch, Lisa R., and Feaster, Daniel J.
- Published
- 2024
- Full Text
- View/download PDF
3. Functions of Resiliency Traits and Processes in Differential Effects of CBSM on Quality of Life in Breast Cancer Survivors: A Moderated Mediation Model
- Author
-
St Fleur, Ruth G., St George, Sara M., Feaster, Daniel J., Lee, Tae Kyoung, and Antoni, Michael H.
- Published
- 2024
- Full Text
- View/download PDF
4. PrEP for people who use opioids: A NIDA clinical trials network survey study in Southern U.S. cities where HIV incidence is high
- Author
-
Hatch, Mary A., Laschober, Tanja C., Paschen-Wolff, Margaret, Ertl, Melissa M., Nelson, C. Mindy, Wright, Lynette, Lancaster, Chloe, Feaster, Daniel J., Forrest, David, Hankey, Colby, Monger, Mauda, Fegley, Joshua P., Irving, Rhonda, Young, Cynthia, Rose, Juliana, Spector, Anya, Dresser, Lauren, Moran, Landhing, Jelstrom, Eve, and Tross, Susan
- Published
- 2024
- Full Text
- View/download PDF
5. Soluble Plasma Proteins of Tumor Necrosis Factor and Immunoglobulin Superfamilies Reveal New Insights into Immune Regulation in People with HIV and Opioid Use Disorder
- Author
-
Ghanta, Priya P., primary, Dang, Christine M., additional, Nelson, C. Mindy, additional, Feaster, Daniel J., additional, Forrest, David W., additional, Tookes, Hansel, additional, Pahwa, Rajendra N., additional, Pallikkuth, Suresh, additional, and Pahwa, Savita G., additional
- Published
- 2024
- Full Text
- View/download PDF
6. Disadvantaged groups have greater spatial access to pharmacies in New York state
- Author
-
Suri, Abhinav, primary, Quinn, James, additional, Balise, Raymond R., additional, Feaster, Daniel J., additional, El-Bassel, Nabila, additional, and Rundle, Andrew G., additional
- Published
- 2024
- Full Text
- View/download PDF
7. Estimating the potential value of MSM‐focused evidence‐based implementation interventions in three Ending the HIV Epidemic jurisdictions in the United States: a model‐based analysis.
- Author
-
Enns, Benjamin, Sui, Yi, Guerra‐Alejos, Brenda C., Humphrey, Lia, Piske, Micah, Zang, Xiao, Doblecki‐Lewis, Susanne, Feaster, Daniel J., Frye, Victoria A., Geng, Elvin H., Liu, Albert Y., Marshall, Brandon D. L., Rhodes, Scott D., Sullivan, Patrick S., and Nosyk, Bohdan
- Subjects
DIAGNOSIS of HIV infections ,HIV ,HIV infection transmission ,QUALITY-adjusted life years ,HIV seroconversion - Abstract
Introduction: Improving the delivery of existing evidence‐based interventions to prevent and diagnose HIV is key to Ending the HIV Epidemic in the United States. Structural barriers in the access and delivery of related health services require municipal or state‐level policy changes; however, suboptimal implementation can be addressed directly through interventions designed to improve the reach, effectiveness, adoption or maintenance of available interventions. Our objective was to estimate the cost‐effectiveness and potential epidemiological impact of six real‐world implementation interventions designed to address these barriers and increase the scale of delivery of interventions for HIV testing and pre‐exposure prophylaxis (PrEP) in three US metropolitan areas. Methods: We used a dynamic HIV transmission model calibrated to replicate HIV microepidemics in Atlanta, Los Angeles (LA) and Miami. We identified six implementation interventions designed to improve HIV testing uptake ("Academic detailing for HIV testing," "CyBER/testing," "All About Me") and PrEP uptake/persistence ("Project SLIP," "PrEPmate," "PrEP patient navigation"). Our comparator scenario reflected a scale‐up of interventions with no additional efforts to mitigate implementation and structural barriers. We accounted for potential heterogeneity in population‐level effectiveness across jurisdictions. We sustained implementation interventions over a 10‐year period and evaluated HIV acquisitions averted, costs, quality‐adjusted life years and incremental cost‐effectiveness ratios over a 20‐year time horizon (2023–2042). Results: Across jurisdictions, implementation interventions to improve the scale of HIV testing were most cost‐effective in Atlanta and LA (CyBER/testing cost‐saving and All About Me cost‐effective), while interventions for PrEP were most cost‐effective in Miami (two of three were cost‐saving). We estimated that the most impactful HIV testing intervention, CyBER/testing, was projected to avert 111 (95% credible interval: 110–111), 230 (228–233) and 101 (101–103) acquisitions over 20 years in Atlanta, LA and Miami, respectively. The most impactful implementation intervention to improve PrEP engagement, PrEPmate, averted an estimated 936 (929–943), 860 (853–867) and 2152 (2127–2178) acquisitions over 20 years, in Atlanta, LA and Miami, respectively. Conclusions: Our results highlight the potential impact of interventions to enhance the implementation of existing evidence‐based interventions for the prevention and diagnosis of HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties
- Author
-
Cerdá, Magdalena, primary, Hamilton, Ava D., additional, Hyder, Ayaz, additional, Rutherford, Caroline, additional, Bobashev, Georgiy, additional, Epstein, Joshua M., additional, Hatna, Erez, additional, Krawczyk, Noa, additional, El-Bassel, Nabila, additional, Feaster, Daniel J., additional, and Keyes, Katherine M., additional
- Published
- 2024
- Full Text
- View/download PDF
9. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
- Author
-
Bartholomew, Tyler S., Plesons, Marina, Serota, David P., Alonso, Elizabeth, Metsch, Lisa R., Feaster, Daniel J., Ucha, Jessica, Suarez Jr., Edward, Forrest, David W., Chueng, Teresa A., Ciraldo, Katrina, Brooks, Jimmie, Smith, Justin D., Barocas, Joshua A., and Tookes, Hansel E.
- Subjects
PRE-exposure prophylaxis ,HIV prevention ,ANTI-HIV agents ,SEXUALLY transmitted diseases ,DRUG abuse ,HIV infections - Abstract
Background: People who inject drugs (PWID) remain a high priority population under the federal Ending the HIV Epidemic initiative with 11% of new HIV infections attributable to injection drug use. There is a critical need for innovative, efficacious, scalable, and community-driven models of healthcare in non-stigmatizing settings for PWID. We seek to test a Comprehensive-TeleHarm Reduction (C-THR) intervention for HIV prevention services delivered via a syringe services program (SSP). Methods: The CHARIOT trial is a hybrid type I effectiveness-implementation study using a parallel two-arm randomized controlled trial design. Participants (i.e., PWID; n = 350) will be recruited from a syringe services program (SSP) in Miami, Florida. Participants will be randomized to receive either C-THR or non-SSP clinic referral and patient navigation. The objectives are: (1) to determine if the C-THR intervention increases engagement in HIV prevention (i.e., HIV pre-exposure prophylaxis; PrEP or medications for opioid use disorder; MOUD) compared to non-SSP clinic referral and patient navigation, (2) to examine the long-term effectiveness and cost-effectiveness of the C-THR intervention, and (3) to assess the barriers and facilitators to implementation and sustainment of the C-THR intervention. The co-primary outcomes are PrEP or MOUD engagement across follow-up at 3, 6, 9 and 12 months. For PrEP, engagement is confirmed by tenofovir on dried blood spot or cabotegravir injection within the previous 8 weeks. For MOUD, engagement is defined as screening positive for norbuprenorphine or methadone on urine drug screen; or naltrexone or buprenorphine injection within the previous 4 weeks. Secondary outcomes include PrEP adherence, engagement in HCV treatment and sustained virologic response, and treatment of sexually transmitted infections. The short and long term cost-effectiveness analyses and mixed-methods implementation evaluation will provide compelling data on the sustainability and possible impact of C-THR on comprehensive HIV prevention delivered via SSPs. Discussion: The CHARIOT trial will be the first to our knowledge to test the efficacy of an innovative, peer-led telehealth intervention with PWID at risk for HIV delivered via an SSP. This innovative healthcare model seeks to transform the way PWID access care by bypassing the traditional healthcare system, reducing multi-level barriers to care, and meeting PWID where they are. Trial Registration: ClinicalTrials.gov NCT05897099. Trial registry name: Comprehensive HIV and Harm Prevention Via Telehealth (CHARIOT). Registration date: 06/12/2023. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment.
- Author
-
Luo, Sean X., Feaster, Daniel J., Liu, Ying, Balise, Raymond R., Hu, Mei-Chen, Bouzoubaa, Layla, Odom, Gabriel J., Brandt, Laura, Pan, Yue, Hser, Yih-Ing, VanVeldhuisen, Paul, Castillo, Felipe, Calderon, Anna R., Rotrosen, John, Saxon, Andrew J., Weiss, Roger D., Wall, Melanie, and Nunes, Edward V.
- Subjects
OPIOID abuse ,DRUG abuse treatment ,RECEIVER operating characteristic curves ,CLINICAL trials monitoring ,DISEASE risk factors - Abstract
Key Points: Question: For individuals undergoing medication treatment for opioid use disorder, can those who will return to opioid use be predicted at the individual level? Findings: In this decision analytical model using a harmonized data set of 2199 adults with opioid use disorder, incorporating treatment entry characteristics and urine drug screen results in the first 3 weeks of treatment improved model performance in predicting return to use. Meaning: These findings suggest that clinicians can use a web-based predictive model to stratify return-to-use risk when delivering care for patients with opioid use disorder. This decision analytical model uses a harmonized data set to develop an individual-level prediction tool to assess the risk of return to use in patients treated for opioid use disorder. Importance: No existing model allows clinicians to predict whether patients might return to opioid use in the early stages of treatment for opioid use disorder. Objective: To develop an individual-level prediction tool for risk of return to use in opioid use disorder. Design, Setting, and Participants: This decision analytical model used predictive modeling with individual-level data harmonized in June 1, 2019, to October 1, 2022, from 3 multicenter, pragmatic, randomized clinical trials of at least 12 weeks' duration within the National Institute on Drug Abuse Clinical Trials Network (CTN) performed between 2006 and 2016. The clinical trials covered a variety of treatment settings, including federally licensed treatment sites, physician practices, and inpatient treatment facilities. All 3 trials enrolled adult participants older than 18 years, with broad pragmatic inclusion and few exclusion criteria except for major medical and unstable psychiatric comorbidities. Intervention: All participants received 1 of 3 medications for opioid use disorder: methadone, buprenorphine, or extended-release naltrexone. Main Outcomes and Measures: Predictive models were developed for return to use, which was defined as 4 consecutive weeks of urine drug screen (UDS) results either missing or positive for nonprescribed opioids by week 12 of treatment. Results: The overall sample included 2199 trial participants (mean [SD] age, 35.3 [10.7] years; 728 women [33.1%] and 1471 men [66.9%]). The final model based on 4 predictors at treatment entry (heroin use days, morphine- and cocaine-positive UDS results, and heroin injection in the past 30 days) yielded an area under the receiver operating characteristic curve (AUROC) of 0.67 (95% CI, 0.62-0.71). Adding UDS in the first 3 treatment weeks improved model performance (AUROC, 0.82; 95% CI, 0.78-0.85). A simplified score (CTN-0094 OUD Return-to-Use Risk Score) provided good clinical risk stratification wherein patients with weekly opioid-negative UDS results in the 3 weeks after treatment initiation had a 13% risk of return to use compared with 85% for those with 3 weeks of opioid-positive or missing UDS results (AUROC, 0.80; 95% CI, 0.76-0.84). Conclusions and Relevance: The prediction model described in this study may be a universal risk measure for return to opioid use by treatment week 3. Interventions to prevent return to regular use should focus on this critical early treatment period. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Bon Sante(Good Health): Factors Influencing PrEP Use Among Haitians/Haitian Americans
- Author
-
Sternberg, Candice A., Daniel, E. Valerie, Marcelin, Dora, Chery, Maurice Junior, Maddy, Krisna, Richard, Danelle, Thomas, Tanya, Ravix, Jovanka, Warner, Joshua, Titus, Micaelle, Francois, Aline, Borick, Joseph, Feaster, Daniel J., Doblecki-Lewis, Susanne, Jones, Deborah L., Alcaide, Maria L., and Dale, Sannisha K.
- Abstract
Background: The HIV/AIDS epidemic has disproportionately affected Black individuals in the USA, and this health disparity has increased over time. Despite the effectiveness of pre-exposure prophylaxis (PrEP) as a prevention tool for HIV, there are disparities in its use, and uptake of this intervention remains low among racial and ethnic minorities, including Haitians/Haitian Americans. In this study, factors influencing PrEP use among Haitians/Haitian Americans in Miami, FL, are explored to provide necessary data to address disparities. Methods: The research team collaborated with local organizations to recruit 30 individuals (Haitians/Haitian Americans) between February 4 and October 1, 2021, and conducted semi-structured interviews. All interviews were audio-recorded and transcribed, and NVivo® was used to analyze the transcripts for emergent themes. Results: The study sample comprised 30 adults of Haitian descent in Miami, FL (50% female, approximately 67% with a high school education or more, mean age = 43.7 ± 13 years, and 74.2% born in Haiti). Four primary themes emerged from the analysis: (1) limited PrEP awareness, (2) underutilization of PrEP, (3) inadequate discussion of HIV prevention strategies, and (4) PrEP delivery encompassing barriers and facilitators for PrEP delivery and promotion strategies. Conclusion: This study indicated that there is a critical need to increase Haitians/Haitian Americans’ knowledge regarding PrEP. Health communication interventions tailored specifically for Haitians/Haitian Americans that target stigma, attitudes toward HIV, and risk perception may be significant in increasing PrEP in this population.
- Published
- 2024
- Full Text
- View/download PDF
12. Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements.
- Author
-
Christine, Paul J., Chahine, Rouba A., Kimmel, Simeon D., Mack, Nicole, Douglas, Christian, Stopka, Thomas J., Calver, Katherine, Fanucchi, Laura C., Slavova, Svetla, Lofwall, Michelle, Feaster, Daniel J., Lyons, Michael, Ezell, Jerel, and Larochelle, Marc R.
- Published
- 2024
- Full Text
- View/download PDF
13. Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial.
- Author
-
Stopka TJ, Babineau DC, Gibson EB, Knott CE, Cheng DM, Villani J, Wai JM, Blevins D, David JL, Goddard-Eckrich DA, Lofwall MR, Massatti R, DeFiore-Hyrmer J, Lyons MS, Fanucchi LC, Harris DR, Talbert J, Hammerslag L, Oller D, Balise RR, Feaster DJ, Soares W, Zarkin GA, Glasgow L, Oga E, McCarthy J, D'Costa L, Chahine R, Gomori S, Dalvi N, Shrestha S, Garner C, Shadwick A, Salsberry P, Konstan MW, Freisthler B, Winhusen J, El-Bassel N, Samet JH, and Walsh SL
- Subjects
- Adult, Humans, Data Analysis, Educational Status, Intention, Adolescent, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Buprenorphine therapeutic use, Opiate Overdose, Opioid-Related Disorders drug therapy
- Abstract
Importance: Buprenorphine significantly reduces opioid-related overdose mortality. From 2002 to 2022, the Drug Addiction Treatment Act of 2000 (DATA 2000) required qualified practitioners to receive a waiver from the Drug Enforcement Agency to prescribe buprenorphine for treatment of opioid use disorder. During this period, waiver uptake among practitioners was modest; subsequent changes need to be examined., Objective: To determine whether the Communities That HEAL (CTH) intervention increased the rate of practitioners with DATA 2000 waivers and buprenorphine prescribing., Design, Setting, and Participants: This prespecified secondary analysis of the HEALing Communities Study, a multisite, 2-arm, parallel, community-level, cluster randomized, open, wait-list-controlled comparison clinical trial was designed to assess the effectiveness of the CTH intervention and was conducted between January 1, 2020, to December 31, 2023, in 67 communities in Kentucky, Massachusetts, New York, and Ohio, accounting for approximately 8.2 million adults. The participants in this trial were communities consisting of counties (n = 48) and municipalities (n = 19). Trial arm randomization was conducted using a covariate constrained randomization procedure stratified by state. Each state was balanced by community characteristics including urban/rural classification, fatal opioid overdose rate, and community population. Thirty-four communities were randomized to the intervention and 33 to wait-list control arms. Data analysis was conducted between March 20 and September 29, 2023, with a focus on the comparison period from July 1, 2021, to June 30, 2022., Intervention: Waiver trainings and other educational trainings were offered or supported by the HEALing Communities Study research sites in each state to help build practitioner capacity., Main Outcomes and Measures: The rate of practitioners with a DATA 2000 waiver (overall, and stratified by 30-, 100-, and 275-patient limits) per 100 000 adult residents aged 18 years or older during July 1, 2021, to June 30, 2022, were compared between the intervention and wait-list control communities. The rate of buprenorphine prescribing among those waivered practitioners was also compared between the intervention and wait-list control communities. Intention-to-treat and per-protocol analyses were performed., Results: A total of 8 166 963 individuals aged 18 years or older were residents of the 67 communities studied. There was no evidence of an effect of the CTH intervention on the adjusted rate of practitioners with a DATA 2000 waiver (adjusted relative rate [ARR], 1.04; 95% CI, 0.94-1.14) or the adjusted rate of practitioners with a DATA 2000 waiver who actively prescribed buprenorphine (ARR, 0.97; 95% CI, 0.86-1.10)., Conclusions and Relevance: In this randomized clinical trial, the CTH intervention was not associated with increases in the rate of practitioners with a DATA 2000 waiver or buprenorphine prescribing among those waivered practitioners. Supporting practitioners to prescribe buprenorphine remains a critical yet challenging step in the continuum of care to treat opioid use disorder., Trial Registration: ClinicalTrials.gov Identifier: NCT04111939.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.